Duvyzat®
(givinostat)



Dosing and Monitoring Guide

INDICATION

DUVYZAT is a histone deacetylase inhibitor indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Hematological Changes: DUVYZAT can cause dose-related thrombocytopenia and other signs of myelosuppression. Monitor blood count every 2 weeks for the first 2 months, at month 3, and every 3 months thereafter. Modify the dosage for confirmed thrombocytopenia. Discontinuation may be needed if abnormalities worsen.

Please see additional Important Safety Information throughout and full Prescribing Information for additional safety information.

Table of contents

Ryan, actual DUVYZAT patient for 6+ years.

Please see additional Important Safety Information throughout and full Prescribing Information for additional safety information.

PROTECTION with twice-daily, oral dosing

DUVYZAT is an oral suspension administered twice daily (can be taken with food)

Weight-based dosing with DUVYZAT

Body weight	Dosage	Oral suspension volume
10 kg to <20 kg	22.2 mg twice daily	2.5 mL twice daily
20 kg to <40 kg	31 mg twice daily	3.5 mL twice daily
40 kg to <60 kg	44.3 mg twice daily	5 mL twice daily
≥60 kg	53.2 mg twice daily	6 mL twice daily

Find the right dose for your patients with the dosing calculator.

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions (cont'd)

Increased Triglycerides: DUVYZAT can cause elevations in triglycerides. Monitor triglycerides at 1 month, 3 months, 6 months, and then every 6 months thereafter. Modify the dosage if fasting triglycerides are verified >300 mg/dL. Treatment with DUVYZAT should be discontinued if triglycerides remain elevated despite adequate dietary intervention and dosage adjustment.

Please see additional Important Safety Information throughout and full Prescribing Information for additional safety information.

Initial testing is required prior to initiating DUVYZAT

Duvyzat® (givinostat)

- Obtain and evaluate baseline platelet counts and triglycerides prior to initiation of DUVYZAT
  - Do not initiate DUVYZAT in patients with a platelet count <150 x 10^9/L

- In patients with underlying cardiac disease or taking concomitant medications that cause QT prolongation, obtain ECGs:
  - When initiating treatment with DUVYZAT
  - During concomitant use if unavoidable
  - When clinically indicated

- Avoid concomitant use with other drugs that prolong the QTc interval
- Withhold DUVYZAT if the QTc interval is >500 ms or the change from baseline is >60 ms

- Closely monitor when DUVYZAT is used in combination with an oral CYP3A4 sensitive substrate or a sensitive substrate of the OCT2 transporter, for which a small change in substrate plasma concentration may lead to serious toxicities

ECG, electrocardiogram; QTc, heart rate–corrected QT interval.

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions (cont'd)

Gastrointestinal Disturbances: Gastrointestinal disturbances, including diarrhea, nausea/vomiting, and abdominal pain were common adverse reactions in DUVYZAT clinical trials. Antiemetics or antidiarrheal medications may be considered during treatment with DUVYZAT. Modify the dosage of DUVYZAT in patients with moderate or severe diarrhea and discontinue treatment if significant symptoms persist.

Please see additional Important Safety Information throughout and full Prescribing Information for additional safety information.

Guidance for ongoing monitoring

After starting DUVYZAT, ongoing laboratory monitoring helps keep patients on track

To facilitate regular monitoring, patients can be directed to a nearby lab, or you can enroll them in the ITF ARC in-home lab monitoring program.

Month	1	2	3	4	5	6	7	8	9	10	11	12
CBC + differential	●●	●●	●			●			●			●
Triglycerides	●		●			●						●

CBC with differential

Monitor every 2 weeks for the first 2 months of treatment, at month 3, and then every 3 months thereafter

Triglycerides

Monitor at 1 month, 3 months, 6 months, and then every 6 months thereafter

After the first 3 months of treatment with DUVYZAT, blood monitoring will become less frequent if your patient's dose remains the same.

In-home lab monitoring is available for patients enrolled in ITF ARC.

CBC, complete blood count.

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions (cont'd)

QTc Prolongation: DUVYZAT can cause prolongation of the QTc interval. Avoid use of DUVYZAT in patients who are at an increased risk for ventricular arrhythmias (including torsades de pointes), such as those with congenital long QT syndrome, coronary artery disease, electrolyte disturbance or in patients taking concomitant medicinal products known to cause QT prolongation. Obtain ECGs prior to initiating treatment with DUVYZAT in patients with underlying cardiac disease or in patients who are taking concomitant medications that cause QT prolongation. If concomitant use cannot be avoided, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold DUVYZAT if the QTc interval is >500 ms or the change from baseline is >60 ms.

Please see additional Important Safety Information throughout and full Prescribing Information for additional safety information.

Expect that you may need to adjust your patients' treatment plans

Duvyzat® (givinostat)

Dose modifications may be needed to manage certain adverse reactions

Many patients taking DUVYZAT require dose modifications to help manage adverse reactions. A dose modification may be needed if any of the following occur:

- Confirmed thrombocytopenia (platelet count <150 x 10^9/L)
- Moderate or severe diarrhea
  - Antiemetics or antidiarrheal medications may be considered during treatment with DUVYZAT. Fluid and electrolytes should be replaced as needed to prevent dehydration
- Fasting triglycerides >300 mg/dL verified by 2 assessments 1 week apart

Based on the severity of these adverse reactions, treatment interruption prior to dosage modification should be considered.

	First dosage modification*		Second dosage modification†	
Body weight	**Dosage**	**Oral suspension volume**	**Dosage**	**Oral suspension volume**
10 kg to <20 kg	17.7 mg twice daily	2 mL twice daily	13.3 mg twice daily	1.5 mL twice daily
20 kg to <40 kg	22.2 mg twice daily	2.5 mL twice daily	17.7 mg twice daily	2 mL twice daily
40 kg to <60 kg	31 mg twice daily	3.5 mL twice daily	26.6 mg twice daily	3 mL twice daily
≥60 kg	39.9 mg twice daily	4.5 mL twice daily	35.4 mg twice daily	4 mL twice daily

*If the adverse reaction(s) persist after the first dosage modification, proceed to the second dosage modification.
†If the adverse reaction(s) persist after the second dosage modification, DUVYZAT should be discontinued.

Withhold DUVYZAT if the QTc interval is >500 ms or the change from baseline is >60 ms.

Following a dose modification for decrease in platelets or increase in triglycerides, restart monitoring.

IMPORTANT SAFETY INFORMATION (cont'd)

Adverse Reactions

The most common adverse reactions reported in >5% of patients treated with DUVYZAT are diarrhea (37%), abdominal pain (34%), thrombocytopenia (33%), nausea/vomiting (32%), hypertriglyceridemia (23%), pyrexia (13%), myalgia (9%), rash (9%), arthralgia (8%), fatigue (8%), constipation (7%), and decreased appetite (7%).

Please see additional Important Safety Information throughout and full Prescribing Information for additional safety information.

ITF ARC now offers an in-home lab monitoring program for your patients

Duvyzat® (givinostat)

ITF ARC's in-home lab monitoring program offers dedicated support that helps alleviate the logistical challenges patients may face with routine lab monitoring

ITF ARC
ACCESS • RESOURCES • CARE

Supporting your patients together

Naven Health, PANTHERx, and Labcorp work together to offer an in-home lab monitoring program to patients enrolled in ITF ARC.

naven health

In-home lab monitoring service provider

The Naven Nurses will communicate directly with patients to schedule appointments.

PANTHERx RARE

Exclusive specialty pharmacy provider for DUVYZAT

In addition to their pharmacy services, PANTHERx will inform you of scheduling issues should a patient miss, reschedule, or cancel their visit to ensure they are staying on track with treatment.

labcorp

Dedicated lab processor

Labcorp will process the patient specimens collected by Naven Health and provide the corresponding results directly to you.

Access the DUVYZAT Patient Start Form and In-Home Lab Monitoring Program Form to get patients enrolled in ITF ARC and the in-home lab monitoring program.

The DUVYZAT In-Home Lab Monitoring Program is only available in each US state and the District of Columbia.

For patients living in NY, NJ, or RI: State laws require Labcorp to bill patients' health insurance for the lab tests included in the DUVYZAT In-Home Lab Monitoring Program. Patients may still be responsible for costs such as co-pays, deductibles, or co-insurance, depending on their insurance plan. Patients without insurance will be billed directly by Labcorp.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Hematological Changes: DUVYZAT can cause dose-related thrombocytopenia and other signs of myelosuppression. Monitor blood count every 2 weeks for the first 2 months, at month 3, and every 3 months thereafter. Modify the dosage for confirmed thrombocytopenia. Discontinuation may be needed if abnormalities worsen.

Please see additional Important Safety Information throughout and full Prescribing Information for additional safety information.

Frequently asked questions about in-home lab monitoring

Duvyzat® (givinostat)

How can I enroll patients in the in-home lab monitoring program?*

- **For patients currently enrolled in ITF ARC:** An additional In-Home Lab Monitoring Program Form is required to initiate in-home laboratory monitoring
- **For new patients starting treatment with DUVYZAT:** Please complete the ITF ARC Patient Start Form and In-Home Lab Monitoring Program Form. Both forms can be faxed or mailed to **PANTHERx**

Do patients need to fast before the in-home visit?

- Patients should fast prior to testing if triglycerides are included in the laboratory panel

How will I receive my patients' lab results?

- **Naven Health** will fax the results to your office within 24 hours of the lab's reporting

What happens if a patient misses their lab draw?

- If a patient misses a scheduled lab draw, and **Naven Health** isn't able to reschedule their appointment within 3 calendar days, **PANTHERx** will notify you. Together, you'll determine whether the visit should be rescheduled within the appropriate time frame or skipped in favor of the next scheduled visit. **Naven Health** will make every effort to reschedule the appointment with the patient or caregiver, when applicable

Are there other ways to help mitigate gastrointestinal disturbances apart from dose modifications?

- Gastrointestinal disturbances, including diarrhea, nausea/vomiting, and abdominal pain, were common adverse reactions in DUVYZAT clinical trials in Duchenne muscular dystrophy. Antiemetics or antidiarrheal medications may be considered during treatment with DUVYZAT. Fluid and electrolytes should be replaced as needed to prevent dehydration

What happens if a dose is modified?

- Please notify **PANTHERx** of any dose modifications so the patient's treatment record can be updated accordingly. The laboratory monitoring schedule should then be adjusted based on the clinical rationale for the dose change

*The DUVYZAT In-Home Lab Monitoring Program is only available in each US state and the District of Columbia.

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions (cont'd)

Increased Triglycerides: DUVYZAT can cause elevations in triglycerides. Monitor triglycerides at 1 month, 3 months, 6 months, and then every 6 months thereafter. Modify the dosage if fasting triglycerides are verified >300 mg/dL. Treatment with DUVYZAT should be discontinued if triglycerides remain elevated despite adequate dietary intervention and dosage adjustment.

Please see additional Important Safety Information throughout and full Prescribing Information for additional safety information.

Frequently asked questions about in-home lab monitoring (cont'd)

Duvyzat® (givinostat)

Who will be reaching out to the patient or caregiver to schedule the lab monitoring?

- Once a completed referral, including patient monitoring consent, has been received from **PANTHERx**, **Naven Health** will contact the patient or caregiver within 24 hours for an introductory call. They will confirm the patient's start date of the lab draw schedule. **Naven Health** will schedule subsequent appointments directly with the patient or caregiver
- **PANTHERx** will notify you directly should a patient or caregiver become unresponsive to rescheduling attempts or if they miss a rescheduled appointment

What happens if there is a Critical Lab Value (CLV) result?

- If a critical lab value (CLV) occurs, **PANTHERx** will inform you within 24 hours. If a critically low value is reported for a patient due for refill, **PANTHERx** will hold the DUVYZAT shipment until they receive further instruction from you

Can I modify the monitoring schedule to my own protocol?

- Lab monitoring should follow the schedule outlined in the Prescribing Information. Limited adjustments to the monitoring protocol may be possible in select situations. Please indicate any requested modifications on the In-Home Lab Monitoring Program Form and/or call **PANTHERx** directly to discuss

What is the estimated turnaround time for lab results?

- Lab samples dropped off at **Labcorp** on the same day as sample collection may be ready as soon as the next day. For lab samples that require shipping via FedEx, results turnaround time is 2 to 4 business days

If you have further questions about ITF ARC or the in-home lab monitoring program, you can contact a case manager at ITF ARC: 1-855-4 ITF ARC (1-855-448-3272), 8 AM–8 PM ET, Monday–Friday.

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions (cont'd)

Gastrointestinal Disturbances: Gastrointestinal disturbances, including diarrhea, nausea/vomiting, and abdominal pain were common adverse reactions in DUVYZAT clinical trials. Antiemetics or antidiarrheal medications may be considered during treatment with DUVYZAT. Modify the dosage of DUVYZAT in patients with moderate or severe diarrhea and discontinue treatment if significant symptoms persist.

Please see additional Important Safety Information throughout and full Prescribing Information for additional safety information.

ITF ARC offers dedicated support to help make it easier for your patients to navigate treatment with DUVYZAT

ITF ARC helps make insurance coverage navigation easier, helps address your patients' financial concerns, and supports adherence to therapy.

See more information on ITF ARC.

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions (cont'd)

QTc Prolongation: DUVYZAT can cause prolongation of the QTc interval. Avoid use of DUVYZAT in patients who are at an increased risk for ventricular arrhythmias (including torsades de pointes), such as those with congenital long QT syndrome, coronary artery disease, electrolyte disturbance or in patients taking concomitant medicinal products known to cause QT prolongation. Obtain ECGs prior to initiating treatment with DUVYZAT in patients with underlying cardiac disease or in patients who are taking concomitant medications that cause QT prolongation. If concomitant use cannot be avoided, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold DUVYZAT if the QTc interval is >500 ms or the change from baseline is >60 ms.

Adverse Reactions

The most common adverse reactions reported in >5% of patients treated with DUVYZAT are diarrhea (37%), abdominal pain (34%), thrombocytopenia (33%), nausea/vomiting (32%), hypertriglyceridemia (23%), pyrexia (13%), myalgia (9%), rash (9%), arthralgia (8%), fatigue (8%), constipation (7%), and decreased appetite (7%).

To report SUSPECTED ADVERSE REACTIONS, contact ITF Therapeutics LLC at 1-833-582-4312 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information throughout and full Prescribing Information for additional safety information.

Reference: DUVYZAT. Prescribing information. ITF Therapeutics; 2024.